Molecular Pathogenesis and Cellular-Based Therapies for Thrombocytopenia
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 4519
Special Issue Editors
Interests: transplant engineering; transplant immunology; genetic engineering; transfusion medicine
Interests: transplantation; cell and gene therapy; immunology; histocompatibility
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Thrombocytopenia is a life-threatening hemostatic disorder with multiple etiologies linked to genetic, environmental or drug-associated factors. In thrombocytopenic patients, low platelet counts are associated with critical bleeding or thromboembolism and predict risk for morbidity and mortality. Platelets are anucleated blood cells produced and introduced into the reticuloendothelial system by megakaryocytes localized in the bone marrow. Recently, the lung was proposed as an additional site for platelet biogenesis. At the site of vascular injury, platelet adhesion, activation and coagulation serve as the first wave of hemostasis. Besides these classic functions, platelets were recently shown to play a relevant role in the modulation of immune responses. Hence, beyond the immediate effect of thrombocytopenia in preventing critical bleeding, low platelet counts may affect disease progression. An effective treatment of thrombocytopenia is tightly dependent on the differential diagnosis. Significant advances in characterizing cellular and molecular mechanisms involved in the development and refractoriness to treatment in auto- and allo-thrombocytopenia have been achieved. Furthermore, relevant technical advances in cell production and storage have been accomplished, and innovative cell therapies have been developed, including the generation of bioengineered platelets. These new developments may constitute an alternative strategy to the transfusion of donor platelets for the management of thrombocytopenic patients.
This Special Issue brings together original research and reviews elucidating molecular mechanisms involved in the pathophysiology of thrombocytopenia, molecular and cellular events of thrombosis, hemostasis maintenance and immune response regulation, as well as newly developed drug-, cell- and gene-based therapeutic strategies for the treatment of thrombocytopenia.
Prof. Dr. Rainer Blasczyk
Prof. Dr. Constança Figueiredo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Immune Thrombocytopenia
- Drug-induced Thrombocytopenia
- HLA
- HPA
- Platelet Transfusion
- Megakaryocyte
- Platelet
- Hematopoiesis
- Cell Therapy
- Gene Therapy
- Thrombosis
